Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
Executive Summary
Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date
You may also be interested in...
PhRMA Feels Deadline Pressure, Reminds FDA Of Flexibility In PDUFA Goals
The Pharmaceutical Research & Manufacturers of America is suggesting that FDA can miss its user fee deadline for a product if prolonging the review would lead to swifter approval than entering a second cycle
PhRMA Feels Deadline Pressure, Reminds FDA Of Flexibility In PDUFA Goals
The Pharmaceutical Research & Manufacturers of America is suggesting that FDA can miss its user fee deadline for a product if prolonging the review would lead to swifter approval than entering a second cycle
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Developing biologics and drugs in tandem for the same target is one method Abbott is using to improve R&D productivity